| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Department of Comparative Medicine, University of Washington, Seattle, WA 98195; College of Veterinary Medicine & Biomedical Sciences, Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO; Department of Microbiology, and Department of Medicine, Division of Infectious Diseases, Emerging Pathogens Institute Mount Sinai School of Medicine, New York, NY 10029; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; Department of Microbiology, University of Washington, Seattle, WA 98195; Department of Immunology, University of Washington, Seattle, WA 98195
* To whom correspondence should be addressed. Email:
carole.baskin{at}asu.edu.
We are still inadequately prepared for an influenza pandemic due to lack of a vaccine effective for subtypes to which the majority of the human population has no prior immunity, and that could be rapidly produced in sufficient quantities. There is therefore an urgent need to investigate novel vaccination approaches. Using a combination of genomic and traditional tools, this study compares the protective efficacy in macaques of an intra-respiratory live influenza vaccine produced by truncating NS1 in the human influenza A/Texas/36/91 (H1N1) virus with a conventional vaccine based on formalin-killed whole virus. After homologous challenge, animals in the live vaccine group had greatly reduced viral replication and pathology in lungs, and reduced upper respiratory inflammation. They also had lesser induction of innate immune pathways in lungs and of interferon-sensitive genes in bronchial epithelium. This post-challenge response contrasted with that shortly after vaccination when higher expression of interferon-sensitive genes was observed in bronchial cells from the live vaccine group. This suggested induction of a strong innate immune response shortly after vaccination with the NS1-truncated virus, followed by greater maturity of the post-challenge immune response, as demonstrated with robust influenza-specific CD4+ T cell proliferation, IgG production, and transcriptional induction of T and B cell pathways in lung tissue. In conclusion, a single respiratory tract inoculation with a NS1-truncated influenza virus was effective in protecting non-human primates from homologous challenge. This protection was achieved in the absence of significant or long-lasting adverse effects and through induction of a robust adaptive immune response.
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Functional Genomic and Serological Analysis of the Protective Immune Response Resulting from Vaccination of Macaques with an NS1-Truncated Influenza Virus
![]()
Abstract
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|